News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Chip and tech stocks led market swings today, with semiconductors driving large-cap gains while small-caps showed outsized moves.
  • ECB Governing Council member Escriva warned the baseline economic outlook is highly uncertain, highlighting unclear inflation and oil-price paths.
  • Talen Energy closed an acquisition of 2,451 MW baseload capacity, boosting cash flow per share and targeting AI data-center power demand.
  • Options volume in Moderna surged to 121,257 contracts by early afternoon, with calls dominating and the June 18, 2026 $65 call most active.
  • The Canadian dollar slid to a 14-month low after Fed remarks lifted U.S. yields, widening the two-year yield gap with Canada.
  • Guyana's U.N. candidate Carolyn Rodrigues-Birkett urged member states to preserve and reform the organization during her confirmation hearing.

Latest Articles

Guggenheim Affirms Positive Outlook on Reddit, Sets $245 Price Target

Guggenheim Affirms Positive Outlook on Reddit, Sets $245 Price Target

Guggenheim has reaffirmed its Buy rating on Reddit (NYSE:RDDT), maintaining a $245 price target based on the platform's advancements in user engagement and promising revenue growth forecasts. Despite current market value suggesting some overvaluation, analysts anticipate significant upside driven by product enhancements and expanded advertising ado…

KeyBanc Upholds Sector Weight for Apple Stock Amid Mixed Growth Signals

KeyBanc Upholds Sector Weight for Apple Stock Amid Mixed Growth Signals

KeyBanc has confirmed its Sector Weight rating on Apple shares, highlighting a balanced near-term risk and reward outlook. KeyBanc upgraded its fiscal first-quarter outlook driven by anticipated gains in iPhone average selling prices and stronger Mac sales, while noting potential challenges for the second half of the fiscal year. Market analysts ma…

Global Finance Leaders Discuss Evolution of World Order Amid Rising Uncertainty

Global Finance Leaders Discuss Evolution of World Order Amid Rising Uncertainty

At the World Economic Forum in Davos, leading finance officials converged to debate the evolution of the global order. While some voices warned of a breach in international cooperation marked by power struggles, key figures, including the European Central Bank President and the International Monetary Fund chief, advocated viewing the developments a…

UBS Targets Crypto Investment Services for Private Bank Elite

UBS Targets Crypto Investment Services for Private Bank Elite

UBS is preparing to introduce cryptocurrency trading capabilities to a select group of private banking clients in Switzerland, with plans for potential expansion into other global markets such as Asia-Pacific and the United States. This initiative reflects growing client interest in digital assets and positions UBS alongside other major financial i…

Keefe, Bruyette & Woods Elevates Horizon Bancorp Price Target to $21 Following Robust Quarterly Earnings

Keefe, Bruyette & Woods Elevates Horizon Bancorp Price Target to $21 Following Robust Quarterly Earnings

Keefe, Bruyette & Woods raised its price target on Horizon Bancorp to $21 from $19, endorsing an Outperform rating after the bank reported better-than-expected earnings. The bank’s higher pre-provision net revenue and net interest margin contributed to stronger top-line performance. Updated guidance and optimistic margin outlook prompted increased …

RBC Capital Raises Definium Therapeutics Price Target, Citing Growth Potential in Mental Health Drug Development

RBC Capital Raises Definium Therapeutics Price Target, Citing Growth Potential in Mental Health Drug Development

RBC Capital has increased the price target for Definium Therapeutics Inc to $36 from $20 and reaffirmed an Outperform rating. This adjustment is based on heightened expectations for the commercial success of Definium’s lead candidate, DT120, currently in late-stage trials for generalized anxiety disorder. The company’s market value stands near $1.6…

Evercore ISI Revises CSX Price Target to $40 Amid Mixed Financial Results

Evercore ISI Revises CSX Price Target to $40 Amid Mixed Financial Results

Evercore ISI has reduced its price objective for CSX to $40 from $41 while keeping an Outperform rating on the company's stock. The adjustment follows CSX's fourth-quarter 2025 earnings report, which revealed earnings per share below estimates and volumes and yields underperforming across segments. Despite these challenges, the company forecasts mo…